[HTML][HTML] RELAY, ramucirumab plus erlotinib (RAM+ ERL) in untreated metastatic EGFR-mutant NSCLC (EGFR+ NSCLC): association between TP53 status and …
M Nishio, L Paz-Ares, M Reck, K Nakagawa… - Clinical Lung Cancer, 2023 - Elsevier
Background Ramucirumab plus erlotinib (RAM+ ERL) demonstrated superior progression-
free survival (PFS) in RELAY, a randomised Phase 3 trial in patients with untreated …
free survival (PFS) in RELAY, a randomised Phase 3 trial in patients with untreated …
RELAY, ramucirumab plus erlotinib versus placebo plus erlotinib in untreated EGFR-mutated metastatic non-small cell lung cancer: exposure–response relationship
K Nakagawa, EB Garon, L Gao, S Callies… - Cancer chemotherapy …, 2022 - Springer
Purpose In RELAY, ramucirumab plus erlotinib (RAM+ ERL) improved progression-free
survival (PFS) in patients with untreated, metastatic, EGFR-mutated, non-small cell lung …
survival (PFS) in patients with untreated, metastatic, EGFR-mutated, non-small cell lung …
[HTML][HTML] RELAY, ramucirumab plus erlotinib versus placebo plus erlotinib in patients with untreated, EGFR-mutated, metastatic non-small cell lung cancer: Europe …
SP Aix, S Novello, EB Garon, K Nakagawa… - Cancer Treatment and …, 2021 - Elsevier
Background In EGFR mutation-positive NSCLC, dual EGFR/VEGFR inhibition compared to
EGFR alone increases anti-tumor efficacy. The Phase III RELAY trial demonstrated superior …
EGFR alone increases anti-tumor efficacy. The Phase III RELAY trial demonstrated superior …
Ramucirumab or placebo plus erlotinib in EGFR‐mutated, metastatic non‐small‐cell lung cancer: East Asian subset of RELAY
M Nishio, T Seto, M Reck, EB Garon, CH Chiu… - Cancer …, 2020 - Wiley Online Library
In the global phase III RELAY study, ramucirumab plus erlotinib (RAM+ ERL) demonstrated
superior progression‐free survival (PFS) to placebo plus erlotinib (PL+ ERL) in untreated …
superior progression‐free survival (PFS) to placebo plus erlotinib (PL+ ERL) in untreated …
RELAY, ramucirumab plus erlotinib versus placebo plus erlotinib in patients with untreated, epidermal growth factor receptor mutation-positive, metastatic non-small …
Introduction RELAY was a global, double-blind, placebo-controlled phase III study that
demonstrated superior progression-free survival (PFS) for ramucirumab plus erlotinib …
demonstrated superior progression-free survival (PFS) for ramucirumab plus erlotinib …
RELAY subgroup analyses by EGFR Ex19del and Ex21L858R mutations for ramucirumab plus erlotinib in metastatic non–small cell lung cancer
Purpose: In EGFR-mutated metastatic non–small cell lung cancer (NSCLC), outcomes from
EGFR tyrosine kinase inhibitors have differed historically by mutation type present, with …
EGFR tyrosine kinase inhibitors have differed historically by mutation type present, with …
RELAY: A multinational, double-blind, randomized Phase 3 study of erlotinib (ERL) in combination with ramucirumab (RAM) or placebo (PL) in previously untreated …
K Nakagawa, EB Garon, T Seto, M Nishio, S Ponce Aix… - 2019 - ascopubs.org
9000 Background: Dual blockade of EGFR and VEGFR pathways in EGFRm NSCLC
augments anti-tumor efficacy versus (v) EGFR inhibition alone. RELAY (NCT02411448) …
augments anti-tumor efficacy versus (v) EGFR inhibition alone. RELAY (NCT02411448) …
Ramucirumab plus erlotinib in patients with untreated, EGFR-mutated, advanced non-small-cell lung cancer (RELAY): a randomised, double-blind, placebo-controlled …
K Nakagawa, EB Garon, T Seto, M Nishio… - The Lancet …, 2019 - thelancet.com
Background Dual blockade of the EGFR and VEGF pathways in EGFR-mutated metastatic
non-small-cell lung cancer (NSCLC) is supported by preclinical and clinical data, yet the …
non-small-cell lung cancer (NSCLC) is supported by preclinical and clinical data, yet the …
[HTML][HTML] Randomized, Double-Blind Phase Ib/III Study of Erlotinib With Ramucirumab or Placebo in Previously Untreated EGFR-Mutant Metastatic Non–Small-Cell …
M Reck, EB Garon, L Paz-Ares, S Ponce, JC Jaime… - Clinical lung cancer, 2018 - Elsevier
Background Despite the likelihood of an initial response to an epidermal growth factor
receptor (EGFR) tyrosine kinase inhibitor (TKI), EGFR-mutant non–small-cell lung cancer …
receptor (EGFR) tyrosine kinase inhibitor (TKI), EGFR-mutant non–small-cell lung cancer …
Effect of erlotinib plus bevacizumab vs erlotinib alone on progression-free survival in patients with advanced EGFR-mutant non–small cell lung cancer: a phase 2 …
TE Stinchcombe, PA Jänne, X Wang, EM Bertino… - JAMA …, 2019 - jamanetwork.com
Importance Erlotinib is a standard first-line therapy for patients with epidermal growth factor
receptor (EGFR)–mutant non–small cell lung cancer (NSCLC). Median progression-free …
receptor (EGFR)–mutant non–small cell lung cancer (NSCLC). Median progression-free …